Barclays lifted their target price on Henkel AG & Co. KGaA from €60.00 ($64.52) to €61.00 ($65.59) and gave the stock an “equal weight” rating in a report on Friday, November 11th.

Source: https://www.dailypolitical.com/2023/02/12/henkel-ag-co-kgaa-otcmktshenky-short-interest-up-58-4-in-january.html

CWM LLC increased its position in Fresenius Medical Care AG & Co. KGaA by 82.0% during the 3rd quarter.

Source: https://www.dailypolitical.com/2023/04/16/fresenius-medical-care-ag-co-kgaa-nysefms-pt-raised-to-24-00.html

Finally, UBS Group set a €62.00 ($66.67) target price on Henkel AG & Co. KGaA in a research report on Tuesday, March 7th.

Source: https://www.dailypolitical.com/2023/03/31/the-goldman-sachs-group-analysts-give-henkel-ag-63-00-price-target.html

Key players profiled include AGC Biologics, Charles River Laboratories, Catalent, Danaher (Cytiva), Lonza, Merck KGaA, and others, contributing to the market's evolution.

Source: https://www.prnewswire.com/news-releases/unleashing-potential-aav-focused-cdmo-market-propelled-by-24-61-cagr-transforming-gene-therapies-301910077.html

Merck KGaA may select molecules for further preclinical and clinical development.

Source: https://medcitynews.com/2023/09/merck-kgaa-expands-in-ai-driven-rd-with-two-drug-discovery-deals/

Sandy Spring Bank acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA during the 4th quarter worth about $27,000.

Source: https://www.dailypolitical.com/2023/05/01/fresenius-medical-care-ag-co-kgaa-nysefms-stock-rating-upgraded-by-deutsche-bank-aktiengesellschaft.html